Indeed, the AH-mAb 2095–2 was strongly bound to scIgG-P on high HER2-expressing cancer cells (Fig. 3c), and as expected, restored the ADCC activity of scIgG-P to a level comparable with that of the intact IgG-P with SKOV3 ovarian cancer cells (Fig. 3d) or SKBR3 breast cancer cells (Fig. 3e) as the target cells. This evidence concerns the gene ERBB2 and ovarian carcinoma.